A MULTIPHASE, PHARMACOKINETICS, SAFETY, AND EFFICACY STUDY OF ASTX030 (AZACITIDINE AND CEDAZURIDINE) AS MONOTHERAPY IN SUBJECTS WITH MYELOID NEOPLASM OR IN COMBINATION WITH VENETOCLAX IN SUBJECTS WITH AML (AZTOUND STUDY)
- Registry ID
- ASTX030-01
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- TAIHO ONCOLOGY INC.
- Start date
- 2025-05-13
- Last update
- 2021-06-30
Conditions
- ACUTE MYELOID LEUKEMIA
- MYELODYSPLASTIC SYNDROME
- CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML-2)
Related clinical trials
- PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES ASSESSING
ZIFTOMENIB IN COMBINATION WITH EITHER STANDARD OF CARE NONINTENSIVE
(VENETOCLAX+AZACITIDINE) OR INTENSIVE (7+3) THERAPY IN PATIENTS WITH
UNTREATED NPM1 MUTATED OR KMT2A REARRANGED ACUTE MYELOID LEUKEMIA
- A PHASE 1 STUDY OF TAK-243 FOR RELAPSED OR REFRACTORY ACUTE MYELOID
LEUKEMIA OR MYELODYSPLASTIC SYNDROMES WITH INCREASED BLASTS
- A PHASE 2, RANDOMIZED, OPEN-LABEL, STUDY OF MOMELOTINIB IN PARTICIPANTS WITH
ANEMIA DUE TO LOW-RISK MYELODYSPLASTIC SYNDROME
- A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY OF
BLEXIMENIB, VENETOCLAX AND AZACITIDINE FOR THE TREATMENT OF
PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
HARBORING KMT2A REARRANGEMENTS OR NPM1 MUTATIONS WHO ARE
INELIGIBLE FOR INTENSIVE CHEMOTHERAPY
- A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF QUIZARTINIB
ADMINISTERED IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY
AND ADMINISTERED AS MAINTENANCE THERAPY IN ADULT PATIENTS WITH NEWLY
DIAGNOSED FLT3-ITD NEGATIVE ACUTE MYELOID LEUKEMIA (QUANTUM-WILD)
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRITERCEPT (KER-050) FOR THE TREATMENT OF TRANSFUSION-DEPENDENT ANEMIA IN ADULT PARTICIPANTS WITH VERY LOW-, LOW-, OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES (MDS) (RENEW)
View on source registry